Literature DB >> 31364116

MiR-105 inhibits gastric cancer cells metastasis, epithelial-mesenchymal transition by targeting SOX9.

J-C Shang1, G-Z Yu, Z-W Ji, X-Q Wang, L Xia.   

Abstract

OBJECTIVE: Gastric cancer is one of the most common gastrointestinal malignancy, which is often diagnosed at an advanced stage. MicroRNA-105 (miR-105) was downregulated and acts as a tumor suppressor in various cancers. The purpose of this study was to explore the molecular mechanisms of miR-105 and sex-determining region Y-box 9 (SOX9) in gastric cancer. PATIENTS AND METHODS: Western blot was performed to display the protein level of E-Cadherin, N-Cadherin, Vimentin and SOX9. Transwell assay was utilized to measure the capacity of migration and invasion. We employed the Luciferase reporter assay to determine miR-105 targeting to SOX9 in gastric cancer.
RESULTS: MiR-105 was downregulated in gastric cancer tissues and cells; it suppressed gastric cancer cell migration, invasion and epithelial-mesenchymal transition (EMT) in gastric cancer. SOX9 was upregulated in gastric cancer cells and had a negative correlation with miR-105. Moreover, the knockdown of SOX9 could inhibit gastric cancer cell migration, invasion and EMT. Furthermore, SOX9 was a target gene of miR-105 and mediated by miR-105. SOX9 could reverse the partial function of miR-105 on cell migration and invasion. In addition, miR-105 downregulation or SOX9 upregulation predicted a poor prognosis.
CONCLUSIONS: We showed that miR-105 was downregulated and inhibited cell migration, invasion and EMT in gastric cancer by binding to SOX9. In addition, we demonstrated that miR-105 downregulation or SOX9 upregulation predicted a poor prognosis. The newly discoverable miR-105/SOX9 axis provides novel insight into gastric cancer treatment.

Entities:  

Year:  2019        PMID: 31364116     DOI: 10.26355/eurrev_201907_18429

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  miR-105 Promotes the Progression and Predicts the Prognosis for Oral Squamous Cell Carcinoma (OSCC).

Authors:  Hong-Yu Zhang; Jian-Hui Ma
Journal:  Cancer Manag Res       Date:  2020-11-10       Impact factor: 3.989

2.  miR-335-5p suppresses gastric cancer progression by targeting MAPK10.

Authors:  Yi Gao; Yanfeng Wang; Xiaofei Wang; Changan Zhao; Fenghui Wang; Juan Du; Huahua Zhang; Haiyan Shi; Yun Feng; Dan Li; Jing Yan; Yan Yao; Weihong Hu; Ruxin Ding; Mengjie Zhang; Lumin Wang; Chen Huang; Jing Zhang
Journal:  Cancer Cell Int       Date:  2021-01-22       Impact factor: 5.722

3.  Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9.

Authors:  Xinxin Kou; Hui Ding; Lei Li; Hongtu Chao
Journal:  Anal Cell Pathol (Amst)       Date:  2021-02-24       Impact factor: 2.916

4.  lncRNA MCF2L-AS1/miR-105/ IL-1β Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance.

Authors:  Mao Cai; Wanle Hu; Chongjie Huang; Chongjun Zhou; Jiante Li; Yanyu Chen; Yaojun Yu
Journal:  Cancer Manag Res       Date:  2021-11-19       Impact factor: 3.989

5.  Integrative analysis of ceRNA network reveals functional lncRNAs associated with independent recurrent prognosis in colon adenocarcinoma.

Authors:  Yinling Mao; Jiachen Lv; Li Jiang; Yihui Wang
Journal:  Cancer Cell Int       Date:  2021-07-05       Impact factor: 5.722

Review 6.  Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer.

Authors:  Tzitzijanik Madrigal; Jesús Hernández-Monge; Luis A Herrera; Claudia Haydée González-De la Rosa; Guadalupe Domínguez-Gómez; Myrna Candelaria; Fernando Luna-Maldonado; Karla G Calderón González; José Díaz-Chávez
Journal:  Front Cell Dev Biol       Date:  2021-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.